General Information
Drug ID
DR00316
Drug Name
Oxaliplatin
Synonyms
ACT 078; Oxaloplatine; Oxaloplatino; Oxalitin; NSC 271670; Oxalato(1,2-diaminocyclohexane)platinum(II); Platinum (II), (cyclohexane-1,2-diammine)oxalato-; CCRIS 9143; Platinum, (1,2-cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')-, (SP-4-2-(trans))-; Platinum, (1,2-cyclohexanediamine-kappaN,kappaN')(ethanedioato(2-)-kappaO1,kappaO2)-, (SP-4-2-(trans))-; Oxaliplatin [USAN:USP:INN:BAN]; CS-0992; HY-17371; NCI60_002138
Drug Type
Small molecular drug
Indication Colorectal cancer [ICD11: 2B91] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=43805"></iframe>
3D MOL 2D MOL
Formula
C8H12N2O4Pt
Canonical SMILES
C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)[O-])[O-].[Pt+4]
InChI
InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+4/p-2/t5-,6-;;/m1../s1
InChIKey
DWAFYCQODLXJNR-BNTLRKBRSA-L
CAS Number
CAS 61825-94-3
Pharmaceutical Properties Molecular Weight 395.3 Topological Polar Surface Area 82.3
Heavy Atom Count 15 Rotatable Bond Count 0
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 6
PubChem CID
43805
PubChem SID
125309438 , 127301221 , 127301222 , 127301223 , 127301224 , 127301225 , 127301226 , 127301227 , 127301228 , 127301229 , 127301230 , 127301231 , 127301232 , 127301233 , 127301234 , 127301235 , 127301236 , 127301237 , 127301238 , 127301239 , 127301240 , 127301241 , 127301242 , 127301243 , 127301244 , 127301245 , 127301246 , 135684119 , 137001870 , 14854529 , 14903423 , 152059544 , 162036207 , 164196639 , 174477519 , 226396770 , 24173438 , 251885690 , 252156659 , 252316548 , 45633994 , 57373686 , 7848852 , 78790585
TTD Drug ID
D0Y3ME
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
CTR1 Transporter Info High affinity copper uptake protein 1 Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
OCT1 Transporter Info Organic cation transporter 1 Substrate [5]
OCT2 Transporter Info Organic cation transporter 2 Substrate [6]
References
1 Oxaliplatin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52.
3 Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23.
4 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
5 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
6 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.